The next phase involves establishing the project as an independent commercial company, focused on securing commercial investment and generating revenue streams as outlined in the business plan. Negotiations are ongoing to identify products for licensing or direct sale to consumers. The core team will also be established.
The team successfully applied for MCST’s GoTo Market funding programme, named GLACIER, securing another €100,000 in funding for the next 1.5 years. This investment enabled them to pursue further IP protection, and push for core platform, and vaccine transporter to be commercialised.
The team successfully applied for a Technology Development project, named ICECAP, securing nearly €230,000 in funding for the next 3 years. This was done in collaboration between the University of Malta and New Energy Ltd. Read more